Purdue is a lead academic institution in a large national institute focused on “digital twins” for semiconductor manufacturing and advanced packaging. The institute, with $285 million in federal funding, marks the latest and largest win in semiconductor strategic research for the university.
Eradivir, a preclinical biotech company, has developed a patent-pending antiviral therapeutic that reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than currently available therapies. A single intranasal dose of EV25, a bispecific small molecule developed by Eradivir, acts faster than the current standard of care, eliminating the detectable virus within 24 hours. EV25 also has a window of efficacy of 96 hours postinfection, which is broader than the current standard of care.
More than 150 Boilermakers from a variety of medical professions converged on Purdue’s West Lafayette campus Nov. 14-16 to participate in the university’s first One Health Alumni Reunion. Attendees networked and took part in timely discussions with Purdue President Mung Chiang, First Lady Kei Hui and fellow alumni as well as Purdue faculty, staff and students.
During International Education Week (Nov. 18-22), Purdue’s Office of Global Partnerships and Global Academic Committee recognize four winners of Purdue’s 2024 Outstanding Leadership in Globalization Award. These university-level awards are given annually to recognize faculty and staff for their dedicated efforts to increase Purdue’s global recognition as a leader in higher education either comprehensively or within a specific land-grant mission pillar.
